US Patent Issued to Novartis on July 15 for "Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors" (American, Canadian Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,358,906, issued on July 15, was assigned to Novartis AG (Basel, Switzerland).

"Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors" was invented by Christopher Adair (Woodstock, Canada), Katsumasa Nakajima (Winchester, Mass.), Rukundo Ntaganda (Weymouth, Mass.), Julien Papillon (Somerville, Mass.) and Troy Douglas Smith (Nashua, N.H.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of preparing compound of Formula (I), or a pharmaceutically acceptable salt thereof,wherein R1 through R6 are as defined herein."

The patent was filed on March 12, 2024, under Application No. 18/602,126.

*For further information, including images, charts...